GlassScriptPhysician profile
Derek W Sears
NPI 1427589514
$5,671.26
in general payments reported to CMS, 2019-2025
23 companies · $1,637 in 2025
The $1,637 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $155 · 2021: $659 · 2022: $840 · 2023: $1,054 · 2024: $1,328 · 2025: $1,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,867 · Education: $120 · Entertainment: $31.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,866.97 |
| Education | $120.03 |
| Entertainment | $31.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,438.25 | 2021-2025 | Clareon, Lensx, Precision7 |
| Abbvie INC. | $694.63 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Mallinckrodt Hospital Products INC. | $607.32 | 2024-2025 | Acthar |
| Oyster Point Pharma, INC. | $269.88 | 2022-2023 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $269.59 | 2021-2022 | |
| Rayner Intraocular Lenses Limited | $264.31 | 2022-2025 | Omidria, Rayone Spheric, Rayone Emv |
| Bausch & Lomb Americas INC. | $242.03 | 2022-2025 | Xiidra, Miebo, Envista Envy Iol |
| Depuy Synthes Sales INC. | $223.49 | 2021-2025 | Matrixmidface, Na |
| Sun Pharmaceutical Industries INC. | $200.90 | 2022-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $186.97 | 2022-2023 | |
| Sight Sciences, INC. | $173.92 | 2021-2025 | Omni Surgical System |
| Tarsus Pharmaceuticals, INC. | $160.97 | 2025 | Xdemvy |
| Glaukos Corporation | $158.62 | 2021-2025 | Idose, Idosetr |
| Amgen INC. | $126.66 | 2025 | Tepezza |
| Biotissue Holdings INC. | $111.97 | 2023-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $97.84 | 2025 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $90.62 | 2021-2024 | Tecnis Iol, Tecnis Simplicity |
| Allergan, INC. | $69.26 | 2021-2022 | |
| Horizon Therapeutics Plc | $34.01 | 2023 | Tepezza |
| Optos, INC. | $31.37 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Dompe US, INC. | $26.19 | 2025 | Oxervate |
| Harrow Eye, LLC | $23.37 | 2025 | Vevye |
| Rxsight INC | $14.54 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Sears listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.